Synaptogenix Inc
TAO Synergies Inc. operates as a biopharmaceutical company. The company is primarily focused on developing a product platform based upon Bryostatin-1, for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X synd… Read more
Synaptogenix Inc (SNPX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.042x
Based on the latest financial reports, Synaptogenix Inc (SNPX) has a cash flow conversion efficiency ratio of -0.042x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-749.07K) by net assets ($17.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Synaptogenix Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Synaptogenix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Synaptogenix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Synaptogenix Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
METALL ZUG N -B- (NDH1.SG)
STU:NDH1
|
0.087x |
|
Marco Holdings Bhd
KLSE:3514
|
0.057x |
|
YesAsia Holdings Limited
PINK:YSASF
|
-0.060x |
|
NDL Ventures Limited
NSE:NDLVENTURE
|
N/A |
|
Lindeman Asia Investment Co. Ltd
KQ:277070
|
0.017x |
|
Top Wealth Group Holding Limited Ordinary Shares
NASDAQ:TWG
|
-0.011x |
|
SeaChange International Inc
NASDAQ:SEAC
|
0.019x |
|
Iervolino & Lady Bacardi Entertainment S.p.A.
PA:ALIE
|
0.019x |
Annual Cash Flow Conversion Efficiency for Synaptogenix Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Synaptogenix Inc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $6.78 Million | $-4.88 Million | -0.721x | -256.43% |
| 2023-12-31 | $25.58 Million | $-5.17 Million | -0.202x | +36.13% |
| 2022-12-31 | $35.41 Million | $-11.21 Million | -0.317x | -21.86% |
| 2021-12-31 | $33.53 Million | $-8.71 Million | -0.260x | +83.52% |
| 2020-12-31 | $5.14 Million | $-8.10 Million | -1.577x | -131.06% |
| 2019-12-31 | $17.42 Million | $-11.89 Million | -0.682x | -135.14% |
| 2018-12-31 | $26.52 Million | $-7.70 Million | -0.290x | -- |